Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JP36 | ISIN: SE0010441584 | Ticker-Symbol: LC8
Tradegate
17.04.24
15:33 Uhr
8,610 Euro
+0,005
+0,06 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CALLIDITAS THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
CALLIDITAS THERAPEUTICS AB 5-Tage-Chart
RealtimeGeldBriefZeit
8,5208,70007:22
8,5608,64517.04.

Aktuelle News zur CALLIDITAS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.04.Calliditas Therapeutics to Attend Conferences in April159STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced...
► Artikel lesen
08.04.Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires190STOCKHOLM, April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a sponsored...
► Artikel lesen
08.04.Calliditas Gets Notice Of Allowance For U.S. Patent Application Covering Setanaxib To Treat Cancer2
08.04.Calliditas Therapeutics: Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment329STOCKHOLM, April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of Allowance...
► Artikel lesen
12.03.Calliditas Therapeutics Receives Seven More Years Of Market Exclusivity For Nefecon In U.S.3
12.03.Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon465SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas")...
► Artikel lesen
06.03.Calliditas Therapeutics AB - 6-K, Report of foreign issuer2
06.03.Calliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®319STOCKHOLM, March 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug exclusivity...
► Artikel lesen
01.03.Calliditas Therapeutics to Attend Investor Conferences in March220STOCKHOLM, March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
► Artikel lesen
21.02.Calliditas Therapeutics AB - 6-K, Report of foreign issuer2
21.02.Calliditas Therapeutics AB reports results for the quarter ended in December - Earnings Summary8
21.02.Calliditas Therapeutics: Calliditas Year-end report, January - December 2023342STOCKHOLM, Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes OCTOBER - DECEMBER...
► Artikel lesen
14.02.Calliditas Therapeutics: Invitation to the presentation of Calliditas' Year-end report January - December 2023390STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday 21 February 2024 at 07.00 a.m. CET. A...
► Artikel lesen
13.02.Calliditas secures new US patent for TARPEYO until 20439
13.02.Calliditas Therapeutics: Calliditas provides patent update366STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office...
► Artikel lesen
09.02.NICE recommends STADA and Calliditas' Kinpeygo to treat rare kidney disease IgAN9
08.01.Calliditas reports strong Q4 growth, eyes future expansion16
08.01.Calliditas Therapeutics AB - 6-K, Report of foreign issuer2
08.01.Calliditas Therapeutics provides business update ahead of JP Morgan conference246STOCKHOLM, Jan. 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today provided a business...
► Artikel lesen
07.01.Calliditas names Maria Törnsén President North America1
Seite:  Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1